These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 30660586)
21. Therapeutic drug monitoring of gentamicin: a 6-year follow-up audit. Ismail R; Haq AH; Azman M; Rahman AF J Clin Pharm Ther; 1997 Feb; 22(1):21-5. PubMed ID: 9292398 [TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens. Barletta JF; Johnson SB; Nix DE; Nix LC; Erstad BL J Trauma; 2000 Nov; 49(5):869-72. PubMed ID: 11086778 [TBL] [Abstract][Full Text] [Related]
23. Population pharmacokinetics of gentamicin in hospitalized patients receiving once-daily dosing. Xuan D; Nicolau DP; Nightingale CH Int J Antimicrob Agents; 2004 Mar; 23(3):291-5. PubMed ID: 15164971 [TBL] [Abstract][Full Text] [Related]
24. Relationship between amikacin blood concentration and ototoxicity in low birth weight infants. Endo A; Nemoto A; Hanawa K; Maebayashi Y; Hasebe Y; Kobayashi M; Naito A; Kobayashi Y; Yamamoto S; Isobe K J Infect Chemother; 2019 Jan; 25(1):17-21. PubMed ID: 30539740 [TBL] [Abstract][Full Text] [Related]
25. A 10-Year Experience of Therapeutic Drug Monitoring (TDM) of Linezolid in a Hospital-wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting TDM in the Majority of Patients? Pea F; Cojutti PG; Baraldo M Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):303-308. PubMed ID: 28419737 [TBL] [Abstract][Full Text] [Related]
26. Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin. Hermida J; Tutor JC Ther Drug Monit; 2006 Jun; 28(3):326-31. PubMed ID: 16778715 [TBL] [Abstract][Full Text] [Related]
27. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis. Abdel-Hady E; El Hamamsy M; Hedaya M; Awad H J Clin Pharm Ther; 2011 Feb; 36(1):45-52. PubMed ID: 21198719 [TBL] [Abstract][Full Text] [Related]
28. Lack of a relationship between the serum concentration of aminoglycosides and ototoxicity in neonates. Setiabudy R; Suwento R; Rundjan L; Yasin FH; Louisa M; Dwijayanti A; Simanjuntak E Int J Clin Pharmacol Ther; 2013 May; 51(5):401-6. PubMed ID: 23557866 [TBL] [Abstract][Full Text] [Related]
29. Population pharmacokinetics of gentamicin and dosing optimization for infants. Medellín-Garibay SE; Rueda-Naharro A; Peña-Cabia S; García B; Romano-Moreno S; Barcia E Antimicrob Agents Chemother; 2015 Jan; 59(1):482-9. PubMed ID: 25385111 [TBL] [Abstract][Full Text] [Related]
30. Aminoglycoside and vancomycin serum concentration monitoring and mortality due to neonatal sepsis in Saudi Arabia. El Desoky ES; Sheikh AA; Al Hammadi AY J Clin Pharm Ther; 2003 Dec; 28(6):479-83. PubMed ID: 14651671 [TBL] [Abstract][Full Text] [Related]
31. Use of aminoglycosides in elderly patients. Pharmacokinetic and clinical considerations. Mörike K; Schwab M; Klotz U Drugs Aging; 1997 Apr; 10(4):259-77. PubMed ID: 9108987 [TBL] [Abstract][Full Text] [Related]
32. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Buijk SE; Mouton JW; Gyssens IC; Verbrugh HA; Bruining HA Intensive Care Med; 2002 Jul; 28(7):936-42. PubMed ID: 12122533 [TBL] [Abstract][Full Text] [Related]
33. Determinants of gentamicin concentrations in critically ill patients: a population pharmacokinetic analysis. Hodiamont CJ; Juffermans NP; Bouman CS; de Jong MD; Mathôt RA; van Hest RM Int J Antimicrob Agents; 2017 Feb; 49(2):204-211. PubMed ID: 28038961 [TBL] [Abstract][Full Text] [Related]
34. Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis. van Altena R; Dijkstra JA; van der Meer ME; Borjas Howard JF; Kosterink JG; van Soolingen D; van der Werf TS; Alffenaar JW Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069654 [TBL] [Abstract][Full Text] [Related]
35. Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review. Jenkins A; Thomson AH; Brown NM; Semple Y; Sluman C; MacGowan A; Lovering AM; Wiffen PJ; J Antimicrob Chemother; 2016 Oct; 71(10):2754-9. PubMed ID: 27494904 [TBL] [Abstract][Full Text] [Related]
36. Population Pharmacokinetics of Amikacin Administered Once Daily in Patients with Different Renal Functions. Aréchiga-Alvarado NA; Medellín-Garibay SE; Milán-Segovia RDC; Ortiz-Álvarez A; Magaña-Aquino M; Romano-Moreno S Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32041715 [TBL] [Abstract][Full Text] [Related]
37. Rationality of administered gentamicin dose in cerebral coma patients treated in an intensive care unit. Janušonis T; Mačiulaitis R; Sveikata A; Milašius A; Kregždytė R Medicina (Kaunas); 2011; 47(2):79-84. PubMed ID: 21734439 [TBL] [Abstract][Full Text] [Related]
38. Evaluating the optimal dose of teicoplanin with therapeutic drug monitoring: not too high for adverse event, not too low for treatment efficacy. Kim SH; Kang CI; Huh K; Cho SY; Chung DR; Lee SY; Kim YJ; Peck KR Eur J Clin Microbiol Infect Dis; 2019 Nov; 38(11):2113-2120. PubMed ID: 31372903 [TBL] [Abstract][Full Text] [Related]
39. Evaluating renal function and age as predictors of amikacin clearance in neonates: model-based analysis and optimal dosing strategies. Illamola SM; Colom H; van Hasselt JG Br J Clin Pharmacol; 2016 Sep; 82(3):793-805. PubMed ID: 27198625 [TBL] [Abstract][Full Text] [Related]